Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 45 Published: December 30, 2021 Report Code: GMDGDHC13185IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    Text to Speech Voices

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever, and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device, and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections drugs in development market research report provides an overview of the Hospital-Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. 

What are the targets of the HA-MRSA Infections pipeline drugs market?

The targets of the HA-MRSA Infections pipeline drugs market are bacterial cell membrane, bacterial cell wall, cell membrane, and DNA.

HA-MRSA Infections pipeline drugs market, by targets

HA-MRSA Infections pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the HA-MRSA Infections pipeline drugs market?

The mechanisms of action of the HA-MRSA Infections pipeline drugs market are Bacterial Cell Membrane Disruptor, Bacterial Cell Wall Disruptor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor.

HA-MRSA Infections pipeline drugs market, by mechanisms of action

HA-MRSA Infections pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the HA-MRSA Infections pipeline drugs market?

The routes of administration in the HA-MRSA Infections pipeline drugs market are oral, topical, inhalational, intravenous, and nasal.

HA-MRSA Infections pipeline drugs market, by routes of administration

HA-MRSA Infections pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the HA-MRSA Infections pipeline drugs market?

The molecule types in the HA-MRSA Infections pipeline drugs market are small molecule, antisense oligonucleotide, peptide, and polymer.

HA-MRSA Infections pipeline drugs market, by molecule types

HA-MRSA Infections pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the HA-MRSA Infections pipeline drugs market?

The key companies in the HA-MRSA Infections pipeline drugs market are Cesa Alliance SA, Destiny Pharma Plc, MGB Biopharma Ltd, Sichuan Saizhuo Pharmaceutical Co Ltd, Techulon Inc, and Valevia UK Ltd.

HA-MRSA Infections pipeline drugs market, by key companies

HA-MRSA Infections pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Bacterial Cell Membrane, Bacterial Cell Wall, Cell Membrane, and DNA
Mechanisms of Action Bacterial Cell Membrane Disruptor, Bacterial Cell Wall Disruptor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor
Routes of Administration Oral, Topical, Inhalational, Intravenous, and Nasal
Molecule Types Small Molecule, Antisense Oligonucleotide, Peptide, And Polymer
Key Companies Cesa Alliance SA, Destiny Pharma Plc, MGB Biopharma Ltd, Sichuan Saizhuo Pharmaceutical Co Ltd, Techulon Inc, and Valevia UK Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections.
  • Reviews of pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key players involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics and enlists all their major and minor projects.
  • Assessment of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections. Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

Cesa Alliance SA

Destiny Pharma Plc

MGB Biopharma Ltd

Sichuan Saizhuo Pharmaceutical Co Ltd

Techulon Inc

Valevia UK Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Overview

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Companies Involved in Therapeutics Development

Cesa Alliance SA

Destiny Pharma Plc

MGB Biopharma Ltd

Sichuan Saizhuo Pharmaceutical Co Ltd

Techulon Inc

Valevia UK Ltd

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Drug Profiles

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Dormant Projects

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Discontinued Products

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Product Development Milestones

Featured News & Press Releases

Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug “Ristazolone Dry Suspension”

Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Cesa Alliance SA, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Destiny Pharma Plc, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by MGB Biopharma Ltd, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Techulon Inc, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline by Valevia UK Ltd, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Dormant Projects, 2021

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

The targets of the HA-MRSA Infections pipeline drugs market are bacterial cell membrane, bacterial cell wall, cell membrane, and DNA.

The mechanisms of action of the HA-MRSA Infections pipeline drugs market are Bacterial Cell Membrane Disruptor, Bacterial Cell Wall Disruptor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor.

The routes of administration in the HA-MRSA Infections pipeline drugs market are oral, topical, inhalational, intravenous, and nasal.

The molecule types in the HA-MRSA Infections pipeline drugs market are small molecule, antisense oligonucleotide, peptide, and polymer.

The key companies in the HA-MRSA Infections pipeline drugs market are Cesa Alliance SA, Destiny Pharma Plc, MGB Biopharma Ltd, Sichuan Saizhuo Pharmaceutical Co Ltd, Techulon Inc, and Valevia UK Ltd.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.